Leading SMEs of India 2022

20 Experts' View Leading SMEs of India 2022 How would you describe the journey of your Company since its inception? What are some of the key milestones of the Company in recent years? With over 35 years of experience into manufacturing, one of the few Companies to be awarded with WHO-cGMP certification since 1996 and continuing to maintain that status. Fredun Pharmaceuticals Ltd over the years has shown a steady CAGR of 28% for the last 12 years. With presence in over 47 Countries. The Company has built its reputation due to its manufacturing prowess and viable business solutions for its clients in terms of quality, large volumes and a mix product portfolio. The organization has always been upgrading, in terms of manufacturing capabilities, new molecules, drug deliveries, and facilities. We have outperformed our CAGR in the last two years due to the consistent efforts of the company over the last decade. With our 850 registrations in Fredun Pharmaceuticals Limited Fredun Medhora Managing Director the pipeline across 12 Countries and having receivedover 100 registrations in the last 18 months which have already been commercialized – FPL is on a trajectory which it had planned more than 5 years ago. With new age products in the field of PET-CARE with their flagship brand of Freossi, FPL has catapulted itself in the forefront of the Vet industry. The products launched are first of its kind in India and also various Allopathic/Herbal/ Food Supplements for chronic and acute ailments.With a robust increase in profitability and top-line and at the lower end of the inflection point, FPL has a long way to go. With latest plants coming in place for Medicated Lotions/Cosmetics/Balm and a State- Of-The-Art plant for Bone-Grafts which will be operational by Mid-May 2023, the speed of growth will not reduce. What are some of the innovative initiatives taken by your Company in recent years? How have those initiatives helped your organization? Fredun Pharmaceuticals Ltd is one the few companies in India, to manufacture products across multiple therapeutic ranges from manufacturing the lowest possible batch sizes to 25 million tablets per day. Although oral drug administration is the most appealing route of drug delivery and tablets being the most preferred dosage form, Fredun Pharmaceuticals Ltd has been able to get manufacturing of multiple drug delivery options all under one roof. Working methodology makes Fredun Pharmaceuticals Ltd approachable & flexible for its clients. Strong and consistent performance over the years has ensured trust with our stakeholders. Fredun Pharmaceuticals Ltd has production capability able to manufacture more than 24 million tablets, 7 million Capsules and over 3,00,000 tubes per day with multiple products simultaneously. With over 340 COPPs and now manufacturing allied products in all classes across 16 locations in India, FPL can boast of the product folio of over 1145 products. The constant upgradation of not just the facility but also the product folio and the upgradation of its formula in terms of manufacturing processes is the key to our growth. What is your Company’s growth strategy for next 3-5 years? Withastrongbase inpharmaceuticals, we as Fredun Pharmaceuticals Ltd are diversifying our portfolio in Veterinary Supplements & Functional Foods and Grooming Products for Pet-Care, Niche Cosmeceuticals and Clinically Tested Nutraceuticals. We are changing our core ethos for the better half of the last decade to transition from a B2B to a B2BC Company. Our goal is to create a few strong brands in the segments that we are currently operating which will enhance not just the numbers but also add value to the society as a whole. Du & Bradstreet